BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-331@pharmaconomics
DTSTAMP:20260707T024905Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:DNTH Phase 3 — claseprubart (estimated date)
DESCRIPTION:Phase 3 trial results for claseprubart in Generalized Myasthenia Gravis are due ~ Dec 31\, 2028. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.globenewswire.com/news-release/2026/07/02/3321543/0/en/Dianthus-Therapeutics-Announces-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-C-4.html\n\nTrack it: https://pharmaconomics.com/e/331
URL:https://pharmaconomics.com/e/331
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:DNTH catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR